- Home
- IMPP vs CDXS Comparison
IMPP vs CDXS Comparison
Compare IMPP & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMPP | CDXS |
|---|---|---|
| Founded | 1981 | 2002 |
| Country | Greece | United States |
| Employees | 49 | N/A |
| Industry | Marine Transportation | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.4M | 256.3M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | IMPP | CDXS |
|---|---|---|
| Price | $4.81 | $2.06 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 278.1K | ★ 872.0K |
| Earning Date | 05-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $138,590,000.00 |
| Revenue This Year | $51.79 | $7.73 |
| Revenue Next Year | $6.97 | $14.24 |
| P/E Ratio | $3.68 | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $2.90 | $0.96 |
| 52 Week High | $6.57 | $3.87 |
Technical Indicators
Market Signals| Indicator | IMPP | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 36.82 |
| Support Level | $4.70 | $1.57 |
| Resistance Level | $5.02 | $2.13 |
| Average True Range (ATR) | 0.19 | 0.16 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 53.72 | 1.55 |
Price Performance
Historical ComparisonAbout IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About CDXS Codexis Inc.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.